Alan G. Levin - 01 Jul 2021 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)

Reporting relationship: Director
Issuer ticker: CRVO
Reported as of: 01 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2021, 21:42:16 UTC
Prior SEC filing: 27 May 2021
Next SEC filing: 02 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ William R. Elder, as attorney-in-fact for the Reporting Person

Key filing fact

Alan G. Levin filed Form 4 for Diffusion Pharmaceuticals Inc. (CRVO) on 06 Jul 2021.

Key facts

This page summarizes Alan G. Levin's Form 4 filing for Diffusion Pharmaceuticals Inc. (CRVO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2021, 21:42.

Change

Previous filing in this sequence was filed on 27 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DFFN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +83,300
Change %
Price: $0.000000
Shares after: 83,300
Date: 01 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 83,300
Exercise price: $0.7200
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021.